- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01191918
The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania
August 30, 2010 updated by: Shanghai Mental Health Center
A Double-Blind, Placebo-Controlled Evaluation of The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania
There is a high rate of partial response to standard thymoleptic medication.
In this study the investigators want to evaluate the safety and efficacy of donepezil as adjunctive treatment to mood stabilizers in bipolar disorder with acute mania.
The investigators hypotheses were that there would be greater mean reduction in manic symptoms with donepezil augmentation of lithium compared with placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Bipolar disorder is a chronic mental illness that affects 1-2% of the general population.
Lithium and valproate are effective for treatment of acute mania for many patients.
However up to half of patients do not respond adequately to currently approved treatments in the acute phase of mania.
More effective treatment for mania are need.
Imbalance in cholinergic and adrenergic tone has long been postulated in the pathophysiology of bipolar disorder.
In the pathophysiology of mania,relative cholinergic hypoactivity was being implicated.
Donepezil is a centrally acting reversible acetylcholinesterase inhibitor.
It is approved for the treatment of Alzheimer's disease.
In an open case series with standardized ratings, addition of donepezil 5-10 mg/day to ongoing mood-stabilizer treatment was associated with marked improvement in treatment-resistant mania.
We want to conduct a 4-week randomized, double-blind, placebo-controlled trial of donepezil as augmentation of lithium in patients with acute manic episode to evaluate the safety and efficacy of donepezil as adjunctive treatment to mood stabilizers in bipolar disorder with acute mania.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients have DSM-IV diagnosis of bipolar disorder with acute manic episode who are admitted as inpatient
- Young Mania Rating Scale (YMRS) total score >20 (based on mean scores of two ratings after admission)
- Physical examination, laboratory results (eg.EKG) from screening visit normal, or abnormal clinically insignificant
Exclusion Criteria:
- Having history of allergy to donepezil or Lithium.
- Having active suicide or homicide attempt or intent
- Having severe medical conditions or taking multiple medications for medical conditions
- Investigational drug treatment within past 30 days
- Having a drug screen positive for any drug of abuse at screening
- Self-report of active substance abuse in the past 2 weeks or substance dependence in the past 2 months
- Diagnosis of schizophrenia, dementia, delirium, seizure disorder, obsessive compulsive disorder, or unstable medical condition
- Administration of any investigational drug within 30 days of screening
- Pregnancy or lactation
- Asthma requiring chronic medication treatment or ongoing use of anticholinergic medications or cholinomimetics
- Other factors that investigator consider not suitable for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: donepezil
donepezil plus Lithium
|
Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
Other Names:
|
Placebo Comparator: Control
Placebo plus Lithium
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total score change of Young Mania Rating Scale
Time Frame: from baseline to week 4
|
Patients were assessed by outcomes assessores at 0 hour(h), 2h,4h,6h,8h,10h,12h,24h,1 week (w), 2w, 4w
|
from baseline to week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Emergent Symptom Scale
Time Frame: from baseline to week4
|
assessed at day 1, week1, week 2, week4
|
from baseline to week4
|
Clinical Global Impression
Time Frame: frome baseline to week 4
|
assessed at 0h, 2h,4h,6h,8h,10h,12h,24h,week1, week2, week4
|
frome baseline to week 4
|
Brief Psychiatric Rating Scale
Time Frame: frome baseline to week 4
|
assessed at 0h, 2h,4h,6h,8h,10h,12h,24h,week1, week2, week4
|
frome baseline to week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Zhen Lu, MD, Shanghai Mental Health Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (Actual)
April 1, 2008
Study Completion (Actual)
April 1, 2008
Study Registration Dates
First Submitted
August 29, 2010
First Submitted That Met QC Criteria
August 30, 2010
First Posted (Estimate)
August 31, 2010
Study Record Updates
Last Update Posted (Estimate)
August 31, 2010
Last Update Submitted That Met QC Criteria
August 30, 2010
Last Verified
August 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Bipolar and Related Disorders
- Bipolar Disorder
- Mania
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Cholinergic Agents
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Antimanic Agents
- Nootropic Agents
- Cholinesterase Inhibitors
- Lithium Carbonate
- Donepezil
Other Study ID Numbers
- Zlu001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
Clinical Trials on Donepezil and Lithium
-
Eisai Inc.Eisai LimitedCompleted
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Samsung Medical CenterEisai Korea Inc.CompletedDementia | Alzheimer's DiseaseKorea, Republic of
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Corium, Inc.CompletedAlzheimer DiseaseUnited States
-
University of CincinnatiUnknownBipolar I DisorderUnited States
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Eisai Inc.PfizerTerminatedCognitive Dysfunction | Down SyndromeUnited States
-
Eisai Inc.PfizerTerminatedCognitive Dysfunction | Down SyndromeUnited States
-
Eisai Inc.CompletedMigraine HeadacheUnited States